Performed as a stand-alone procedure or as an adjunct to cataract surgery, ABiC™ is a new MIGS procedure that can comprehensively restore the natural outflow pathways for your glaucoma patients.

30 Years of Ophthalmic Innovation

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For nearly 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

Canaloplasty for Glaucoma.
Restore the Natural Outflow Pathways.

Canaloplasty revitalizes all of the natural aqueous outflow channels, ensures excellent IOP reduction, and does not produce a bleb or result in bleb-related complications – providing an unprecedented level of efficacy and safety in the surgical treatment of glaucoma.

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

Retinal Rejuvenation. Naturally – from Ellex.

Our latest research program, Retinal Rejuvenation Therapy (2RT) aims to develop a non-damaging laser treatment for early age-related macular degeneration (AMD) – the leading cause of blindness in the developed world.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 20,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

Ellex is committed to helping you better diagnose, manage and treat a wide range of visual problems and eye diseases. Whether you are involved in the treatment and diagnosis of cataract, glaucoma or retinal disease, Ellex has a solution for your practice, and for your patients.

Product Portfolio


Offering superior energy control, a sharp-edged aiming beam and the fastest firing rate at 3 shots per second, Ellex’s proprietary SLT technology allows you to visualize the TM in greater detail, and to perform procedures faster and with improved accuracy.


Canaloplasty revitalizes aqueous outflow, provides excellent IOP control, and does not require a bleb or result in bleb-related complications – providing an unprecedented level of efficacy and safety in the surgical treatment of glaucoma.


YAG laser vitreolysis offers a simple outpatient-based treatment for vitreous opacities and strands. Highly effective, it has a low complication rate and offers a high degree of patient satisfaction. Featuring perfectly coaxial illumination and ultra-low energy optical breakdown, Ultra Q Reflex™ is ideally suited to the treatment of floaters.


The tough demands of today’s new-generation intraocular lenses (IOLs) require an ever-increasing level of accuracy during YAG surgery. For this reason, Ellex YAG lasers feature state-of-the-art technology designed to achieve precise optical breakdown at the lowest energy levels possible.


Ellex solid-state photocoagulators provide safe, predictable and consistent energy delivery through a true, continuous-wave laser beam. Offering superior energy distribution from beginning to end of exposure, and across the full diameter of the treatment spot, each system delivers consistently better performance in the treatment of retinal disease.

Retinal Rejuvenation

A non-thermal laser therapy, Retinal Rejuvenation Therapy (2RT™) stimulates a natural, biological healing response in the eye to treat early Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).


Ultrasound is one of the most fundamental diagnostic tools in ophthalmology. Even in an era of high-tech OCT scanning and digital imaging, ultrasound is the only means to obtain a crucial view of the posterior segment when there is a dense cataract or vitreous hemorrhage in the eye.

SLT website

The website provides access to a comprehensive database of information, including treatment protocols and an interactive bibliography.

Canaloplasty website

An online resource dedicated to Canaloplasty for physicians and patients, the website features a number of educational and practice marketing tools, including a comprehensive video library.


The website provides a wealth of treatment information based on the experience of clinicians worldwide. Topics covered include how to qualify patients for treatment and optimal treatment techniques.


The pressure damage of glaucoma causes a gradual blurring of vision and, if left untreated, can result in total, irreversible blindness. If you suffer from glaucoma, there are several treatment options available. SLT or Selective Laser Trabeculoplasty is a gentle, low-energy laser therapy, which triggers a natural healing response in the eye in order to reduce intraocular pressure. Canaloplasty is an advanced surgical treatment, which works by improving your eye’s natural drainage system.

Learn more about glaucoma.


Vitreous Strands and Opacities (Floaters)

If you suffer from vitreous strands and opacities (commonly referred to as “eye floaters”), then you are already familiar with the frustrating visual disturbance caused by these cobweb and cloud-like shadows. A pain-free, non-invasive laser procedure, vitreolysis can provide much-needed relief from your eye floaters – and help you take back your quality of vision.

Learn more about floaters.


Age-Related Macular Degeneration (AMD)

A chronic eye disease, AMD is caused by damage to the eye’s macula and can result in vision loss in the central field of vision, including blurred central vision or a blind spot. Early detection is crucial. Detecting changes early through regular check-ups with your optometrist or ophthalmologist can help to slow the progression of AMD.

Learn more about AMD.


Diabetic Eye Disease

High blood sugar levels can damage blood vessels in the retina. This damage is referred to as Diabetic Retinopathy. If untreated over the long-term, Diabetic Retinopathy can cause visual impairment and blindness. In order to preserve vision and prevent progression of Diabetic Retinopathy, it is important to take control of your blood sugar levels, blood pressure, and blood cholesterol.

Learn more about diabetic eye disease.


SLT. The Gentle Alternative for Glaucoma

SLT is a gentle laser therapy, which triggers a natural healing response in the eye to reduce the intraocular pressure associated with glaucoma. It effectively lowers eye pressure in the majority of patients, but the length of time that pressure remains low depends on many factors, including: age and type of glaucoma.

Watch a video about SLT.

Interview Con Moshegov

Don’t Let Eye Floaters Cloud Your Vision

Also known as floater laser treatment, vitreolysis is a non-invasive, pain-free procedure that can eliminate the visual disturbance caused by floaters. It is performed in your ophthalmologist’s office and typically takes 20-60 minutes per treatment session.

Watch a video about vitreolysis.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.

ASX Releases

Trading Update for the Half-Year Ended 31 December 2015

29 January 2016
Ellex expects to report a profit before tax of approximately A$1.8 million for the six months ended 31 December 2015. The result will be a material increase in the profit before tax of A$1.3 million reported for the six months ended 31 December 2014.

Ellex expands production facilities to meet anticipated demand

22 January 2016
22 January 2016 Ellex expands production facilities to meet anticipated demand Adelaide, Australia, 22 January 2016 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for diagnosis and treatment of eye disease, today announced that it has entered into a conditional contract to acquire a building in the northern suburbs of Adelaide, South Australia which will provide additional production capacity in order to meet increasing demand for its ophthalmic laser and ultrasound products. “Demand for our products is strong and we expect it to remain so for the foreseeable future. We moved into our current premises, in the City of Adelaide, 15 years ago and have now outgrown that site. This new building provides us with 50% more floor space and there is room for further expansion on the site, if required, by extending the building”, commented Mr Tom Spurling, CEO. The building has 4,500 square metres of floor space and is situated on 2.18 hectares of land in Mawson Lake

Ellex iTrack™ Achieves Further Market Traction and will be Featured at Major US Tradeshow

4 November 2015
Ellex announced that its Ab Interno Canaloplasty procedure (dubbed ABiC™), performed with the Company’s patented iTrack™ microcatheter, will for the first time feature in the official scientific program of the American Academy of Ophthalmology (AAO). The AAO is the pre-eminent ophthalmic conference globally and attracts approximately 10,000 ophthalmologists each year.

View Share Price


Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.

Corporate Governance

Share Trading Policy

Register as a New Distributor